Skip to main content

Advertisement

SpringerLink
Log in

Early relapse with tumefactive MS lesion upon initiation of fingolimod therapy

  • Letter to the Editor
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Visser F, Wattjes MP, Pouwels PJ, Linssen WH, van Oosten BW (2012) Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 79:2000–2003

    Article  PubMed  Google Scholar 

  2. Pilz G, Harrer A, Wipfler P, Oppermann K, Sellner J et al (2013) Tumefactive MS lesions under fingolimod: a case report and literature review. Neurology 81:1654–1658

    Article  PubMed  Google Scholar 

  3. Hellmann MA et al (2014) Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy. J Neurol Sci 344(1-2):193–197. doi:10.1016/j.jns.2014.06.013

    Article  CAS  PubMed  Google Scholar 

  4. Totaro R, Carmine CD, Carolei A (2014) Tumefactive demyelinating lesions in patients with relapsing remitting multiple sclerosis treated with Fingolimod. J Neurol Neurophysiol S12:006. doi:10.4172/2155-9562.S12-006

    Google Scholar 

  5. Fleming J, West M (2014) Reversible Cerebral Vasoconstriction Syndrome and Fingolimod: Culprit or Innocent Bystander (P2.224). Neurology 82(10 Supplement):P2.224

    Google Scholar 

Download references

Conflict of interest

V. Van Pesch has received travel grants and honoraria for consultancy and lectures from from Biogen Idec, Bayer Schering, Sanofi Aventis, Genzyme, Merck Serono and Novartis Pharma. Other authors report no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any author.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Author information

Authors and Affiliations

  1. Neurology Department of Hospital of Arlon, 137, Rue des Déportes, 6700, Arlon, Belgium

    Sabina Boangher, Sophie Goffette & Pascal Mespouille

  2. Neurology Department, Cliniques Universitaires St-Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium

    Vincent Van Pesch

Authors
  1. Sabina Boangher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie Goffette
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vincent Van Pesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pascal Mespouille
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sabina Boangher.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boangher, S., Goffette, S., Van Pesch, V. et al. Early relapse with tumefactive MS lesion upon initiation of fingolimod therapy. Acta Neurol Belg 116, 95–97 (2016). https://doi.org/10.1007/s13760-015-0495-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-015-0495-z

Keywords

Search

Navigation